Skip to main content
SpringerLink
Log in

Clinical predictors of failing one dose of methotrexate for ectopic pregnancy after in vitro fertilization

  • Assisted Reproduction Technologies
  • Published:
Journal of Assisted Reproduction and Genetics Aims and scope Submit manuscript

Abstract

Purpose

The aim of this study is to investigate the clinical predictors of failure of a single dose of methotrexate (MTX) for management of ectopic pregnancy after in vitro fertilization (IVF).

Methods

A retrospective cohort study was performed of women who conceived ectopic pregnancies following fresh or frozen IVF cycles at an academic infertility clinic between 2007 and 2014, and received intramuscular MTX (50 mg/m2). Successful single-dose MTX treatment was defined as a serum beta-human chorionic gonadotropin (hCG) decline ≥15% between days 4 and 7 post-treatment. Logistic regression models adjusted for oocyte age, number of embryos transferred, and prior ectopic pregnancy were used to estimate the adjusted odds ratio (OR) (95% confidence interval [CI]) of failing one dose of MTX.

Results

Sixty-four patients with ectopic pregnancies after IVF were included. Forty required only one dose of MTX (62.5%), while 15 required additional MTX alone (up to four total doses, 23.4%), and 9 required surgery (14.1%). By multivariable logistic regression, the highest tertiles of serum hCG at peak (≥499 IU/L, OR = 9.73, CI 1.88–50.25) and at first MTX administration (≥342 IU/L, OR = 4.74, CI 1.11–20.26), fewer embryos transferred (OR = 0.37 per each additional embryo transferred, CI 0.19–0.74), and adnexal mass by ultrasound (OR = 3.65, CI 1.10–12.11) were each correlated with greater odds of requiring additional MTX and/or surgery.

Conclusion

This is the first study to report that in women with ectopic pregnancies after IVF, higher hCG—though well below treatment failure thresholds previously described in spontaneous pregnancies—fewer embryos transferred, and adnexal masses are associated with greater odds of failing one dose of MTX. These findings can be used to counsel IVF patients regarding the likelihood of success with single-dose MTX.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Perkins KM, Boulet SL, Kissin DM, Jamieson DJ. Risk of ectopic pregnancy associated with assisted reproductive technology in the United States, 2001–2011. Obstet Gynecol. 2015;125:70–8.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Practice Committee of American Society for Reproductive Medicine. Medical treatment of ectopic pregnancy: a committee opinion. Fertil Steril. 2013;100:638–44.

    Article  Google Scholar 

  3. Huang B, Hu D, Qian K, Ai J, Li Y, Jin L, et al. Is frozen embryo transfer cycle associated with a significantly lower incidence of ectopic pregnancy? An analysis of more than 30,000 cycles. Fertil Steril. 2014;102:1345–9.

    Article  PubMed  Google Scholar 

  4. Li Z, Sullivan EA, Chapman M, Farquhar C, Wang YA. Risk of ectopic pregnancy lowest with transfer of single frozen blastocyst. Hum Reprod. 2015;30:2048–54.

    Article  CAS  PubMed  Google Scholar 

  5. Clayton HB, Schieve LA, Peterson HB, Jamieson DJ, Reynolds MA, Wright VC. Ectopic pregnancy risk with assisted reproductive technology procedures. Obstet Gynecol. 2006;107:595–604.

    Article  PubMed  Google Scholar 

  6. Fang C, Huang R, Wei LN, Jia L. Frozen-thawed day 5 blastocyst transfer is associated with a lower risk of ectopic pregnancy than day 3 transfer and fresh transfer. Fertil Steril. 2015;103:655–61.e3.

    Article  PubMed  Google Scholar 

  7. Rombauts L, McMaster R, Motteram C, Fernando S. Risk of ectopic pregnancy is linked to endometrial thickness in a retrospective cohort study of 8120 assisted reproduction technology cycles. Hum Reprod. 2015;30:2846–52.

    CAS  PubMed  Google Scholar 

  8. Malak M, Tawfeeq T, Holzer H, Tulandi T. Risk factors for ectopic pregnancy after in vitro fertilization treatment. J Obstet Gynaecol Can. 2011;33:617–9.

    Article  PubMed  Google Scholar 

  9. Cohen A, Bibi G, Almog B, Tsafrir Z, Levin I. Second-dose methotrexate in ectopic pregnancies: the role of beta human chorionic gonadotropin. Fertil Steril. 2014;102:1646–9.

    Article  CAS  PubMed  Google Scholar 

  10. Barnhart KT, Gosman G, Ashby R, Sammel M. The medical management of ectopic pregnancy: a meta-analysis comparing "single dose" and "multidose" regimens. Obstet Gynecol. 2003;101:778–84.

    PubMed  Google Scholar 

  11. Sendy F, AlShehri E, AlAjmi A, Bamanie E, Appani S, Shams T. Failure rate of single dose methotrexate in management of ectopic pregnancy. Obstet Gynecol Int. 2015;2015:902426.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Erdem M, Erdem A, Arslan M, Oç A, Biberoğlu K, Gürsoy R. Single-dose methotrexate for the treatment of unruptured ectopic pregnancy. Arch Gynecol Obstet. 2004;270:201–4.

    Article  CAS  PubMed  Google Scholar 

  13. Krissi H, Peled Y, Eitan R, Bishara A, Goldchmit C, Ben-Haroush A. Single-dose methotrexate injection for treatment of ectopic pregnancy in women with relatively low levels of human chorionic gonadotropin. Int J Gynaecol Obstet. 2013;121:141–3.

    Article  CAS  PubMed  Google Scholar 

  14. Lipscomb GH, McCord ML, Stovall TG, Huff G, Portera SG, Ling FW. Predictors of success of methotrexate treatment in women with tubal ectopic pregnancies. N Engl J Med. 1999;341:1974–8.

    Article  CAS  PubMed  Google Scholar 

  15. Nowak-Markwitz E, Michalak M, Olejnik M, Spaczynski M. Cutoff value of human chorionic gonadotropin in relation to the number of methotrexate cycles in the successful treatment of ectopic pregnancy. Fertil Steril. 2009;92:1203–7.

    Article  CAS  PubMed  Google Scholar 

  16. Menon S, Colins J, Barnhart KT. Establishing a human chorionic gonadotropin cutoff to guide methotrexate treatment of ectopic pregnancy: a systematic review. Fertil Steril. 2007;87:481–4.

    Article  CAS  PubMed  Google Scholar 

  17. McLaren JF, Barnhart KT, Sammel MD, Appleby DH, Butts SF. Success of the two-dose methotrexate protocol for treatment of ectopic pregnancy in women with a history of prior ectopic pregnancy. J Reprod Med. 2014;59:379–84.

    CAS  PubMed  Google Scholar 

  18. Rabischong B, Tran X, Sleiman AA, Larraín D, Jaffeux P, Aublet-Cuvelier B, et al. Predictive factors of failure in management of ectopic pregnancy with single-dose methotrexate: a general population-based analysis from the Auvergne Register, France. Fertil Steril. 2011;95:401–4.

    Article  CAS  PubMed  Google Scholar 

  19. Cirik DA, Kinay T, Keskin U, Ozden E, Altay M, Gelisen O. Success rates of single-dose methotrexate and additional dose requirements among women with first and previous ectopic pregnancies. Int J Gynaecol Obstet. 2016;133:49–52.

    Article  PubMed  Google Scholar 

  20. Imudia AN, Awonuga AO, Doyle JO, Kaimal AJ, Wright DL, Toth TL, et al. Peak serum estradiol level during controlled ovarian hyperstimulation is associated with increased risk of small for gestational age and preeclampsia in singleton pregnancies after in vitro fertilization. Fertil Steril. 2012;97:1374–9.

    Article  CAS  PubMed  Google Scholar 

  21. Refaat B, Dalton E, Ledger WL. Ectopic pregnancy secondary to in vitro fertilisation-embryo transfer: pathogenic mechanisms and management strategies. Reprod Biol Endocrinol. 2015;13:30.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Doubilet PM. Ultrasound evaluation of the first trimester. Radiol Clin N Am. 2014;52:1191–9.

    Article  PubMed  Google Scholar 

  23. Barnhart KT, Sammel MD, Rinaudo PF, Zhou L, Hummel AC, Guo W. Symptomatic patients with an early viable intrauterine pregnancy: HCG curves redefined. Obstet Gynecol. 2004;104:50–5.

    Article  PubMed  Google Scholar 

  24. National Institute for Biological Standards and Control. WHO International Standard 4th IS Chorionic Gonadotropin, Human NIBSC code: 75/589. https://www.nibsc.org/documents/ifu/75-589.pdf. Accessed 20 May 2016.

  25. Men CJ, Bormann CL, Walsh BW, Racowsky C. Is the presence of an uncleaved embryo on day 3 a useful predictor of outcomes following day 5 transfer? J Assist Reprod Genet. 2015;32:1379–84.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Gardner DK, Schoolcraft WB. Culture and transfer of human blastocysts. Curr Opin Obstet Gynecol. 1999;11:307–11.

    Article  CAS  PubMed  Google Scholar 

  27. Cheung LP, Lam PM, Lok IH, Chiu TT, Yeung SY, Tjer CC, et al. GnRH antagonist versus long GnRH agonist protocol in poor responders undergoing IVF: a randomized controlled trial. Hum Reprod. 2005;20:616–21.

    Article  CAS  PubMed  Google Scholar 

  28. Tummn IS, Daniel SA, Kaplan BR, Nisker JA, Yuzpe AA. Randomized, prospective comparison of luteal leuprolide acetate and gonadotropins versus clomiphene citrate and gonadotropins in 408 first cycles of in vitro fertilization. Fertil Steril. 1992;58:563–8.

    Article  Google Scholar 

  29. Surrey ES, Bower J, Hill DM, Ramsey J, Surrey MW. Clinical and endocrine effects of a microdose GnRH agonist flare regimen administered to poor responders who are undergoing in vitro fertilization. Fertil Steril. 1998;69:419–24.

    Article  CAS  PubMed  Google Scholar 

  30. Dragisic KG, Davis OK, Fasouliotis SJ, Rosenwaks Z. Use of a luteal estradiol patch and a gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation for in vitro fertilization in poor responders. Fertil Steril. 2005;84:1023–6.

    Article  CAS  PubMed  Google Scholar 

  31. Mickey RM, Greenland S. The impact of confounder selection criteria on effect estimation. Am J Epidemiol. 1989;129:125–37.

    Article  CAS  PubMed  Google Scholar 

  32. Bouyer J, Coste J, Shojaei T, Pouly JL, Fernandez H, Gerbaud L, et al. Risk factors for ectopic pregnancy: a comprehensive analysis based on a large case–control, population-based study in France. Am J Epidemiol. 2003;157:185–94.

    Article  PubMed  Google Scholar 

  33. Barnhart K, Hummel AC, Sammel MD, Menon S, Jain J, Chakhtoura N. Use of "2-dose" regimen of methotrexate to treat ectopic pregnancy. Fertil Steril. 2007;87:250–6.

    Article  CAS  PubMed  Google Scholar 

  34. Brady P, Imudia AN, Awonuga AO, Wright DL, Styer AK, Toth TL. Pregnancies of unknown location after in vitro fertilization: minimally invasive management with Karman cannula aspiration. Fertil Steril. 2014;101:420–6.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women’s Hospital and Harvard Medical School, 75 Francis St., Boston, MA, 02115, USA

    Paula C. Brady, Leslie V. Farland & Elizabeth S. Ginsburg

  2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, 677 Huntington Avenue, Boston, MA, 02115, USA

    Stacey A. Missmer & Leslie V. Farland

  3. Department of Obstetrics, Gynecology and Reproductive Biology, College of Human Medicine, Michigan State University, 15 Michigan St NE, Grand Rapids, MI, 49503, USA

    Stacey A. Missmer

Authors
  1. Paula C. Brady
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stacey A. Missmer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Leslie V. Farland
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Elizabeth S. Ginsburg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paula C. Brady.

Ethics declarations

Ethical statement

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. For this type of study, formal consent is not required.

Sources of funding

None.

Conflict of interest

Dr. Ginsburg’s disclosures are honoraria and royalties from Up To Date, Springer Inc., and Advance Medical. The other authors (Drs. Brady, Missmer, and Farland) declare that they have no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Brady, P.C., Missmer, S.A., Farland, L.V. et al. Clinical predictors of failing one dose of methotrexate for ectopic pregnancy after in vitro fertilization. J Assist Reprod Genet 34, 349–356 (2017). https://doi.org/10.1007/s10815-016-0861-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10815-016-0861-7

Keywords

Search

Navigation